PALO ALTO, Calif., Sept. 4, 2019 /PRNewswire/ -- Kodiak
Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical
company specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases, today announced that
presentations on its research will be made at EURETINA 2019
Congress being held from September 5
– 8 in Paris, France.
"We continue to be pleased with the promising efficacy and
safety data of KSI-301," said Victor
Perlroth, M.D., Kodiak's Chief Executive Officer. "At
EURETINA, we will report on outcomes with over 100 patients dosed
and a growing safety database with over 250 injections of KSI-301.
The data being presented continue to demonstrate the potential for
KSI-301 to be a first-line intravitreal anti-VEGF therapy."
Details of the presentations are below.
EURETINA 2019 Congress
Oral Presentation: Novel anti-VEGF antibody biopolymer
conjugate KSI-301 with potential for extended durability in retinal
vascular diseases: first-time results from a phase 1b study in patients with wAMD, DME and RVO
Presenter: Pravin U. Dugel, M.D. -- Clinical Professor,
Department of Ophthalmology, Roski Eye Institute, Keck School of
Medicine, University of Southern
California; Managing Partner, Retinal Consultants of
Arizona, Retinal Research
Institute, Phoenix, AZ
Presentation date and time: Thursday, September 5, 2019
–11:59am CEST
Oral Presentation: Extended durability in exudative
retinal diseases using a new class of molecules: novel anti-VEGF
antibody biopolymer conjugate KSI-301: first-time results of the
phase 1b study in patients with wAMD,
DME and RVO
Presenter: Pravin U. Dugel, M.D. -- Clinical Professor,
Department of Ophthalmology, Roski Eye Institute, Keck School of
Medicine, University of Southern
California; Managing Partner, Retinal Consultants of
Arizona, Retinal Research
Institute, Phoenix, AZ
Presentation date and time: Sunday, September 8, 2019 –
9:48am CEST
The slide presentations will be available on the Kodiak Investor
Relations website at http://ir.kodiak.com/ at the time of the
presentations.
About KSI-301
KSI-301 is an investigational therapy built on the Company's ABC
Platform and is designed to maintain potent and effective drug
levels in ocular tissues for longer than existing agents. Kodiak's
objective with KSI-301 is to improve real-world outcomes for
patients with retinal vascular diseases and to enable earlier
treatment and prevention of vision loss for patients with diabetic
eye disease.
About Kodiak Sciences Inc.
Kodiak™ is a clinical-stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases. We are focused on bringing new
science to the design and manufacture of next generation retinal
medicines to prevent and treat the leading causes of blindness
globally. Our ABC Platform™ merges the fields of antibody-based and
chemistry-based therapies and is at the core of Kodiak's discovery
engine. Kodiak's lead product candidate, KSI-301, is a novel
anti-VEGF antibody biopolymer conjugate being developed for the
treatment of retinal vascular diseases including age-related
macular degeneration and diabetic eye diseases. Kodiak has
leveraged its ABC Platform to build a pipeline of product
candidates in various stages of development including KSI-501, our
bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of
neovascular retinal diseases with an inflammatory component. Kodiak
is based in Palo Alto, CA. For
more information, visit www.kodiak.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking
statements are not based on historical fact and include statements
regarding our platform technology and potential therapies, future
development plans, clinical and regulatory objectives and the
timing thereof, anticipated design of planned clinical trials,
expectations regarding the potential efficacy and commercial
potential of our product candidates, including KSI-301, the
anticipated presentation of data, the results of our research and
development efforts and our ability to advance our product
candidates into later stages of development. Forward-looking
statements generally include statements that are predictive in
nature and depend upon or refer to future events or conditions, and
include words such as "may," "will," "should," "would," "expect,"
"plan," "believe," "intend," "pursue," and other similar
expressions among others. Any forward-looking statements are based
on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to, clinical trials
may not demonstrate safety and efficacy of any of our product
candidates; our efforts to advance the clinical development of
additional product candidates may not be successful; any of our
product candidates may fail in development; the preliminary safety,
efficacy and durability data for our KSI-301 product candidate from
the Phase 1 study will not continue or persist; cessation or delay
of any of the ongoing clinical studies and/or our development of
KSI-301 may occur; future potential regulatory milestones of
KSI-301, including those related to current and planned clinical
studies may be insufficient to support regulatory submissions or
approval; anticipated presentation of data at upcoming conferences
may not occur; our research and development efforts and our ability
to advance our product candidates into later stages of development
may fail; any one or more of our product candidates may not be
successfully developed, approved or commercialized; adverse
conditions in the general domestic and global economic markets; as
well as the other risks identified in our filings with the
Securities and Exchange Commission. For a discussion of other risks
and uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled "Risk Factors"
in our most recent Form 10-Q, as well as discussions of potential
risks, uncertainties, and other important factors in our subsequent
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof and
Kodiak undertakes no obligation to update forward-looking
statements, and readers are cautioned not to place undue reliance
on such forward-looking statements.
"Kodiak," "ABC Platform" and the Kodiak logo are registered
trademarks or trademarks of Kodiak Sciences Inc. in various
jurisdictions.
View original
content:http://www.prnewswire.com/news-releases/kodiak-sciences-announces-upcoming-presentations-at-euretina-meeting-300912050.html
SOURCE Kodiak Sciences Inc.